Eris Biotech Analysis: $500K Raised
What is Eris Biotech?
Eris Biotech develops orally administered small-molecule cancer therapies that aim to block immune evasion. The website describes a first-in-class small-molecule inhibitor and says the approach reawakens the immune system to fight cancer. The site also states the drug is safe for patients, but it does not provide detailed clinical data on the homepage.
Location
3300 N Triumph Blvd, Lehi, Utah 84043, US
Employees
1-10
Founded
2023
Investors
- Y Combinator
Product Features & Capabilities
- cancer therapeutics using small molecules, hypoxia-activated prodrugs (HAPs), targeted delivery to tumor sites, engagement of the immune system to fight tumors, reduced systemic toxicity
How much Eris Biotech raised
Pre-Seed - $500,000
March 8, 2024Lead Investor: Y Combinator
Who are the founders of Eris Biotech
RG
Rachel Garlick
Founder
EW
Evita Weagel
Founder
Market Focus
Eris Biotech primarily focuses on the biotechnology industry, specifically in the development of innovative cancer treatments that target the tumor microenvironment.
Competitors Overview
Eris Biotech operates in the oncology sector, focusing on innovative cancer treatments that target the tumor microenvironment. Its main competitors include:
-
Incendia Therapeutics:
- Overview: A precision oncology biotech company dedicated to reprogramming the tumor microenvironment.
- Notable Differences: Incendia emphasizes rigorous research involving spatial characterization of the tumor microenvironment and multi-omics approaches. This may provide a more comprehensive understanding of tumor biology compared to Eris Biotech's focus on activating cancer drugs specifically within tumors.
- Advantages: Their platform is based on groundbreaking research, which may lead to more effective treatment strategies.
-
Cybrexa Therapeutics:
- Overview: This company is developing a new class of therapeutics that directly targets the tumor microenvironment.
- Notable Differences: Cybrexa utilizes a tumor-targeting platform called "alphalex," which aims to enhance the efficacy of existing cancer therapeutics through innovative applications and combinations.
- Advantages: Their approach to microRNA silencing for cancer therapy specifically targets the tumor microenvironment, potentially offering unique treatment options that complement Eris Biotech's methodologies.
These competitors share a focus on the tumor microenvironment but differ in their specific technologies and research approaches, which may provide them with distinct advantages in the oncology market.
See something that needs updating? Suggest edits to this profile.